Sanofi extends collaboration with Medicines for Malaria Venture for Phase IIb trials

8 July 2015

French drug major Sanofi (Euronext: SAN) is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria.

This collaboration began as a three-year research project agreement in May 2011 in order to develop drug candidates from Sanofi compounds selected for their potential activity against malarial parasites. The project has been evaluated at each stage by a joint steering committee, applying MMV’s criteria for compound progression.

To date, the collaboration has yielded two potential treatments: OZ439/Piperaquine and OZ439/Ferroquine. Each of these are a single, fixed-dose combination therapy independent of artemisin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK